Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034

Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034

Key Highlights

The total diagnosed prevalent cases of Complement 3 Glomerulopathy in the 7MM was around 5,700 in 2023, which is expected to grow during the forecast period 2024-2034.

In the 7MM, the maximum cases of diagnosed prevalent cases of Complement 3 Glomerulopathy were reported in the United States, accounting for nearly 58% cases of the 7MM in 2023.

Germany had the highest number of prevalent cases of Complement 3 Glomerulopathy among EU4 and the UK. The diagnosed prevalent population of DDD and C3GN in Germany were found to be ~160 and ~370, respectively in 2023.

In 2023, Japan accounted for roughly 200 diagnosed prevalent population cases of Complement 3 Glomerulopathy.

DelveInsight’s “Complement 3 Glomerulopathy – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Complement 3 Glomerulopathy, historical and forecasted epidemiology of Complement 3 Glomerulopathy in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Complement 3 Glomerulopathy Disease Understanding

Complement 3 Glomerulopathy Overview

The term complement 3 glomerulopathy was adopted by expert consensus in 2013 to define a group of rare kidney diseases driven by dysregulation of the complement cascade. The major features of Complement 3 Glomerulopathy include high levels of protein in the urine (proteinuria), blood in the urine (hematuria), reduced amounts of urine, low levels of protein in the blood, and swelling in several areas of the body.

Complement 3 Glomerulopathy is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The accumulation of C3 without a significant amount of classical or lectin complement component in the glomeruli suggests dysregulation of the alternative complement pathway as the underlying pathogenetic mechanism. This finding, in the absence or near absence of immunoglobulin deposits in a patient with the classic clinical features of glomerulonephritis, is the single diagnostic criterion. The rarity of Complement 3 Glomerulopathy makes it challenging to derive precise incidence and prevalence of the indication; however, several small cohort studies have generated estimates of limited reliability.

Complement 3 Glomerulopathy Diagnosis

In most cases, diagnosis of Complement 3 Glomerulopathy requires a renal biopsy and careful review of light microscopy, immunofluorescence, and electron microscopy. Broadly, Complement 3 Glomerulopathy is defined as the predominant staining of C3 on immunofluorescence (IF) when compared to immunoglobulin (intensity >2 orders of magnitude). Complement 3 Glomerulopathy is classified by electron microscopy findings into DDD or C3GN, depending on the presence or absence of dense osmiophilic intramembranous deposits. However, the various diagnostic tests opted for establishing a Complement 3 Glomerulopathy diagnosis are as follows: Urine test, Blood test, Glomerular filtration rate (GFR), and Kidney biopsy.

Complement 3 Glomerulopathy Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent population of Complement 3 Glomerulopathy, type-specific diagnosed prevalent population of Complement 3 Glomerulopathy, and age-specific diagnosed prevalent population of Complement 3 Glomerulopathy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.

The diagnosed prevalent population of Complement 3 Glomerulopathy, in the United States, was found to be ~3,300 in 2023.

In EU4 and the UK, the diagnosed prevalent population of Complement 3 Glomerulopathy was found to be the maximum in Germany, followed by Spain in 2023. While the lowest number of cases were found in Italy.

In Japan, adults are more prevalent in Complement 3 Glomerulopathy compared to pediatrics.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Complement 3 Glomerulopathy, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.

A detailed review of the Complement 3 Glomerulopathy epidemiology, detailed assumptions, and rationale behind our approach is included in the report.

A detailed review of current challenges in establishing the diagnosis.

Complement 3 Glomerulopathy Report Insights

Patient Population

Patient population by gender and age

Country-wise Epidemiology Distribution

Report Key Strengths

11 Years Forecast

The 7MM Coverage

Complement 3 Glomerulopathy Epidemiology Segmentation

Complement 3 Glomerulopathy Report Assessment

Epidemiology Segmentation

Current Diagnostic Practices

FAQs

What are the disease risk and burdens and of complement 3 glomerulopathy epidemiology? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to complement 3 glomerulopathy epidemiology?

What is the historical and forecasted to complement 3 glomerulopathy epidemiology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Which age group is the largest contributor in patients affected with complement 3 glomerulopathy epidemiology?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.